Cipla is a leading pharmaceutical from India with presence across the world. It was established in 1935 as Chemical Industrial & Pharmaceutical Laboratories Ltd and changed to its current name in 1984. The company has a vast portfolio with more than 1,500 products in the market. The company’s business is divided into three strategic units - Active Pharmaceutical Ingredients (API), Respiratory and Cipla Global Access. Its largest market is India which contributed 39 per cent to its revenues in FY18, followed by Africa and North America with contribution of 22 per cent and 17 per cent, respectively. Its total income reached Rs 11,779.69 crore (US$ 1.83 billion). In 9M FY19, total income of the company reached Rs 9,400.61 crore (US$ 1.30 billion).
Company Website: www.cipla.com
Cipla – Caring for Life.
|2017||Received approval for Q-TIB from World Health Organisation (WHO)|
|2016||Sold its stake in Chase|
|2014||Acquired minority stake in US-based Chase Pharma|
|2013||Acquired 100 per cent stake in Medpro South Africa|
|2005||Set up formulation facility in Baddi, Himachal Pradesh|
|2002||Set up four state-of-the-art manufacturing facilities in Goa|
|1999||Strategic partnership with Ranbaxy|
|1987||Launched several new products|
|1985||Approval from FDA for bulk drug manufacturing plants|
|1984||Name changed to Cipla|
|1952||Set up of first research division|
|1935||Incorporated in Mumbai, Maharashtra as Chemical Industrial & Pharmaceutical Laboratories Ltd|
Updated: May, 2019